<DOC>
	<DOCNO>NCT00441662</DOCNO>
	<brief_summary>Melanoma common primary tumour occur inside eye . For 20-years , possible , many case , use local delivery radiation eye treat type tumour , avoid need surgically remove affected eye . This treatment , however , often complicate radiation-induced loss vision , month year treatment . The aim research project investigate potential prevention radiation complication eye give anti-inflammatory medication ( long-acting steroid ) form local injection around eye time treatment , 4-months 8-months following treatment . This medication ( name ‘ triamcinolone ’ ) successfully use treat similar complication diabetic eye disease , example , good safety profile . The rationale study attempt preserve vision , addition preserve eye , patient affect eye tumour , therefore preserve quality life patient .</brief_summary>
	<brief_title>Sub-Tenon Triamcinolone Prevention Radiation-Induced Macular Edema</brief_title>
	<detailed_description>BACKGROUND : Uveal melanoma common primary intraocular malignancy . Plaque radiation ( brachytherapy ) emerge common treatment current management uveal melanoma , complicate visual loss close 70 % patient 10 year follow-up . Strategies prevention early treatment radiation retinopathy ( radiation maculopathy particular ) need develop improve visual outcome follow eye-conserving treatment uveal melanoma . Triamcinolone , long act locally-administered corticosteroid , establish benefit macular oedema cause . PURPOSE : This study evaluate efficacy sub-Tenon triamcinolone prevention radiation maculopathy patient undergo plaque radiotherapy uveal melanoma . DESIGN : A prospective randomise control study . STUDY POPULATION : 170 patient undergoing plaque radiation treatment uveal melanoma . SETTING : Ocular Oncology Service , Wills Eye Hospital , Philadelphia , USA . INTERVENTION : Triamcinolone acetonide ( 40 mg 1 cc ) inject sub-Tenon space use sterile technique time plaque radiotherapy 4 8 month later . OUTCOME MEASURES : Visual acuity , optical coherence tomographic ( OCT ) analysis macular architecture foveal thickness , 4 , 8 , 12 month follow brachytherapy . EXCLUSION CRITERIA : Pre-existing macular disease ( e.g . age-related macular degeneration , diabetic maculopathy , vascular occlusion , macular hole ) ; prior retinal detachment ; medium opacity preclude accurate OCT imaging ; history intraocular pressure elevation relate corticosteroid treatment -'steroid responder ' ; history glaucoma .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Triamcinolone hexacetonide</mesh_term>
	<mesh_term>Triamcinolone</mesh_term>
	<mesh_term>Triamcinolone Acetonide</mesh_term>
	<mesh_term>Triamcinolone diacetate</mesh_term>
	<criteria>Uveal melanoma new diagnosis , undergo plaque radiation treatment Preexisting macular disease agerelated macular degeneration diabetic maculopathy preexist retinal vascular occlusion macular hole surface wrinkle retinopathy prior retinal detachment medium opacity preclude accurate OCT image know 'steroid responder ' glaucoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2007</verification_date>
	<keyword>Melanoma</keyword>
	<keyword>Uvea</keyword>
	<keyword>Macula</keyword>
	<keyword>Edema</keyword>
	<keyword>Plaque radiotherapy</keyword>
	<keyword>Brachytherapy</keyword>
	<keyword>Triamcinolone</keyword>
</DOC>